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Research into cell and gene therapies is globally dispersed, which creates 
scientific opportunities, but in turn, significant commercial challenges. 
In order to successfully bring promising scientific endeavors through to 
commercial opportunity, greater cross-border coordination of supply 
side activity considerations such as academic institutions, funding gaps, 
intellectual property, and commercial entities as well as demand-side is-
sues of reimbursement, regulatory policy, stakeholder engagement and 
patient engagement should be advocated for.
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After decades of scientific advance 
but commercial mis-starts, the field 
of regenerative medicine is finally 
offering more than simply a prom-
ise of transformative healthcare 
[1,2]. Recent commercial advances 
in CAR T-cell therapy based on chi-
meric antigen receptors for cancer 
treatment, such as the FDA’s 2017 
approval of Novartis’s Kymriah (ti-
sagenlecleucel; licensed from the 
University of Pennsylvania) [3], 
may now be the tip of the iceberg 
in emerging opportunities to treat 
conditions that have few tradition-
al clinical options. Multiple treat-
ments based on technologies such 
as cell therapy, gene therapy, and 
tissue engineered products finally 
appear to be emerging from the lab 
into the healthcare market. Yet, if 
we do not learn from the failures in 
the past, the recent advances could 
stall again [4].
A succinct timeline of cell therapy, 
gene therapy and tissue engineering 
is shown in Figure 1, highlighting 
the scientific strength of the field 
and the limited commercial im-
pact. Two key questions arise here: 
first, why has commercial impact 
taken so long and, second, what 
does the field need to do to rein-
force the signs of emerging success 
in the market? At the core of these 
questions is the need to coordinate 
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 f FIGURE 1
A timeline of notable discoveries (green), clinical breakthroughs (blue), commercial successes (yellow) 
and set-backs (red) in the three allied fields of cell therapy, gene therapy and tissue engineering. 
Cell therapy products consist of cells which convey a mechanistic, biological or regenerative process. Gene therapy products are 
biological products comprise recombinant nucleic acids which have a therapeutic effect on a patient such as fixing a section of faulty 
genetic code. Tissue engineered products are a class of material, synthetic or biological in origin, both with or without a cellular 
payload with the primary goal of regeneration of patient tissue.
EXPERT INSIGHT 
  471Cell & Gene Therapy Insights - ISSN: 2059-7800  
the globally dispersed activities of 
regenerative medicine science and 
commercialization.
The global dispersion of re-
generative medicine research is a 
strength in generating scientific 
breakthroughs, while also raising 
commercial challenges. Worldwide, 
three hubs stand out for bio-sci-
ences: Boston-Cambridge in Mas-
sachusetts, the San Francisco Bay 
Area in California, and the ‘Gold-
en Triangle’ defined by London, 
Cambridge, and Oxford in the UK 
[5,6]. The scientific strength in these 
hubs have bred ecosystems of ven-
ture funding and specialized hu-
man capital that support commer-
cial translation from the lab to the 
market. In regenerative medicine, 
the Boston-Cambridge region is 
the undoubted leader able to attract 
globally mobile research, clinical ex-
pertise, industry, and funding. San 
Francisco has the benefit of access 
to the diverse range of technolo-
gy start-ups in the Silicon Valley. 
For Europe, the ‘Golden Triangle’ 
stands out as the cornerstone of the 
industry on the continent. 
Yet, key elements of regenerative 
medicine science span the globe 
far beyond these centres, including 
bases in other parts of the U.S., as 
well as in Japan, Sweden, Austra-
lia, Canada, Israel, Germany, and 
many other countries. Successful 
commercialization of products 
based on regenerative medicine sci-
ence typically requires integration 
of advances from multiple geog-
raphies. This trend is clearly evi-
denced by the accelerating pace of 
mergers and acquisitions within the 
field. Acquisitions include not only 
product and technology portfolios 
such as Universal Cells by Astellas 
Pharma [7] and Kite Pharma by 
Gilead [8], but also the acquisition 
of manufacturing assets such as 
Progenitor Cell Technologies by 
Hitachi Chemical Energy Technol-
ogy Co. [9] Nonetheless, although 
there have been some successes, the 
commercial support ecosystem has 
often struggled to integrate across 
the multiple regions.
To foster innovation in the re-
generative medicine sector, we ad-
vocate an emphasis on strategies 
that embrace an increasingly glob-
ally coordinated perspective. These 
strategies need to include supply 
side considerations of academic 
institutions, funding gaps, intel-
lectual property, and commercial 
vendors as well as demand side is-
sues of reimbursement, regulatory 
policy, stakeholder engagement, 
and patient engagement. This arti-
cle discusses current weaknesses, re-
cent advances, and potential future 
pathways. By detailing these areas, 
we advocate an increasingly strate-
gic and collaborative approach to 
innovation across the global regen-
erative medicine sector.
SUPPLY SIDE 
CHALLENGES:GETTING 
TO THE MARKET
Academic institutions
Universities and medical schools 
throughout the world are major 
centres for regenerative medicine 
research that has potential for trans-
lation into clinical practice [10]. Yet 
academic institutions commonly 
struggle to commercialise research 
effectively. Indeed, most University 
Technology Transfer Offices run at 
a loss [11]. 
In part, the marketplace chal-
lenges occur because much of 
the research that university-based 
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scientists undertake in is not com-
mercially viable, at least in the near 
term. Instead, academic research 
commonly provides a base of sci-
ence that may contribute to appli-
cations only in the distant future or, 
indeed, not at all [12]. 
A more focal problem, though, 
lies in integrating regenerative med-
icine projects with near term com-
mercial potential that span multi-
ple institutions, often in multiple 
countries. The issue is that academ-
ic commercialization efforts typical-
ly focus on individual institutions. 
The key challenge here lies in devel-
oping protocols and partnerships 
for combining intellectual property 
that spans institutional boundaries. 
Fortunately, some trans-institu-
tional models are emerging. A salient 
example is the German Fraunhofer 
Society which utilises the ‘Fraun-
hofer Model’ [13] to link more than 
60 semi-autonomous institutes with 
universities and industries. The pow-
er of this model comes from the en-
hanced ability to exploit knowledge 
based opportunities through linking 
otherwise fragmented organisations 
[14]. This trend towards collabora-
tive enterprise in academic institu-
tions shows signs of expanding, with 
initiatives such as the emerging Eu-
ropean Research Area encouraging 
combined research proposals across 
the European continent [15].
Funding gaps
Part of the inherent challenge with 
the commercialisation pathway is 
financial. Regenerative medicine 
diverges from some sectors in that 
new opportunities require a large 
degree of financing over a long and 
uncertain timeline in order to ex-
ploit their potential – commonly 
hundreds of millions of dollars over 
a decade or more long horizon. 
Uncertainty arises from the often 
untested regulatory pathways [16], 
contested intellectual property port-
folios, and difficulty in establishing 
clinical efficacy in the same manner 
as pharmaceuticals or devices. 
Given the uncertainty, many 
funders are reluctant to invest in 
regenerative medicine. Historically, 
most stem cell therapy companies 
have failed. Among those that have 
undertaken initial public offerings 
(IPOs), most companies face stock 
prices that fall as much as 90% from 
their IPO levels [17].
The reluctance may be beginning 
to subside. BlueRock Therapeutics 
in Toronto and New York, for in-
stance, received up to $225 million 
in Series A financing from Bayer 
and Versant Ventures in 2016, for 
instance. Investors appear to in-
creasingly able to project market 
size, reimbursement rates, and reg-
ulatory paths as the first products 
have tested the waters. In turn, 
there has been substantial growth in 
frequency and value of acquisitions 
in the sector, signalling confidence 
in the market potential [18].
Nonetheless, despite the growing 
evidence of market support, there is 
still a substantial role for early stage 
research funding from public sourc-
es. Public financial support can help 
de-risk the progress made through 
academic scientific advances to a 
stage where the level of risk is ac-
ceptable to privately backed com-
mercial organisations. 
Many early stage funding 
programs have existed in many 
countries, offering real support 
for initial ventures. The oldest 
government-backed regenerative 
medicine institutions, the Cali-
fornia Institute for Regenerative 
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Medicine (CIRM), has stimulated 
a translationally focussed industry 
through grants with translationally 
focussed milestones. Two other key 
government-sponsored agencies are 
CCRM (Centre for Commercial-
ization of Regenerative Medicine) 
in Canada and the Cell and Gene 
Therapy Catapult (CGTC) in the 
UK. These programmes act as incu-
bators, allowing access to facilities or 
services with flexible arrangements 
for reimbursement, which could in-
clude taking a stake in a company. 
Flexible approaches not only in ser-
vices or facilities rendered to clients, 
but also how these organisations are 
recompensed is an exemplar of the 
approach the field requires in order 
to overcome the complex challeng-
es in advanced therapy develop-
ment, manufacturing, regulation, 
and reimbursement [19].
A secondary role of such govern-
ment supported organisations is to 
act as a champion for the field [19]. 
Competition in the field is intense 
not just between industries, but 
between geographic regions. The 
U.K. pioneered the field of mono-
clonal antibodies, yet lost out to the 
U.S. and Asia in translating these 
products, as the country lacked 
commercial infrastructure needed 
to develop and finance products to 
commercial scale. With cell therapy 
offering commercial potential on 
the same order as biologics, there 
are strong incentives to help gener-
ate needed infrastructure in support 
of local science. 
Again, though, the tendency for 
each government to focus its fund-
ing and other support on a single 
country, or even local region within a 
country, risks missing the global span 
of funding and infrastructure needed 
to support commercialization.  The 
sector could easily continue in the 
trap in which a scattered set of ini-
tiatives around the globe does not 
achieve needed coordination.
Intellectual property
Protection of inventions through 
patents and other intellectual prop-
erty (IP) protection has long been 
viewed as essential to foster inno-
vation in healthcare. In its simplest 
form, intellectual property protects 
an invention by facilitating an ex-
clusive monopoly in the market for 
a set amount of time. In return, the 
inventor must disclose the funda-
mental nature of the invention so 
that when the protection expires the 
benefits may be more widely dif-
fused. The overall goal is to provide 
a balance between reimbursement 
to inventors, incentives to contin-
ue to innovate rather than simply 
garner rents from prior innovations, 
and broad-based access.
To improve the current system 
of intellectual property protection 
it would be beneficial to emphasize 
transparency and consistency in the 
patent process globally. In an ef-
fort to fulfil these requirements the 
World Trade Organization (WTO) 
has worked towards an internation-
al agreement on Trade-Related As-
pects of Intellectual Property Rights 
(TRIPS). This agreement outlines 
the minimal requirements for IP to 
enhance the compliance between 
WTO member states. Particular 
emphasis is paid to standards, en-
forcement, and dispute settlement 
for IP issues. 
In regenerative medicine, the 
patent rights for CRISPR-Cas9 
provide an example that emphasizes 
the need for clarity in claims when 
filing patent applications. The pat-
ent rights were initially filed by the 
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University of California, Berkeley, 
indicating that CRISPR-Cas9 could 
be used to cut isolated DNA.  This 
method was further advanced at 
the Broad Institute in Massachu-
setts, which highlighted the use 
of CRISPR-Cas9 to edit DNA in 
eukaryotic cells. Despite the earlier 
patent filing at Berkeley, the Broad 
Institute was granted patent rights 
first. The conflict between the insti-
tutions has led to uncertainty in the 
market and slowed commercial use 
of the technology [20].
The global scale of regenera-
tive medicine research means that 
commercialization efforts need to 
engage with different IP regimes, 
despite the TRIPS efforts for uni-
formity. On a global scale, Japan 
and the U.S. are leaders in patent 
applications and granted patent 
rights, but have key differences in 
IP regimes. The life science patent 
environment in Japan limits pat-
ents granted to only those products 
that serve an industrial application, 
with medical activities and diagnos-
tic methods for treatment on the 
human body not qualifying to be 
patentable. This raises contractu-
al challenges when integrating key 
technologies across borders.
Commercial strategies
Production of regenerative medi-
cine products diverges from those 
established for existing pharmaceu-
ticals and biologics. Attempts to 
shoehorn these into existing frame-
works have yielded poor outcomes. 
A classic exemplar is the immuno-
therapy Provenge, commercialized 
by Seattle’s Dendreon Corporation 
in 2010, which had a sound clinical 
product yet failed financially and led 
to the company’s bankruptcy [21].
Different regenerative medicine 
products necessitate varying man-
ufacturing and business strategies. 
Broadly, there are two compet-
ing paradigms for production and 
sales: Centralised, where manufac-
turing capacity is located primarily 
in a few locations and one compa-
ny takes the lead in marketing a 
product; and decentralised, where 
production units are geographical-
ly dispersed and multiple partners 
share marketing activities [22,23]. 
The centralised strategy has been 
the dominant production and sales 
scenario since the industrial revo-
lution. Its key benefit is the reduc-
tion in costs through economies 
of scale. Conversely, decentralised 
strategies are relatively new scenar-
ios that reflect the dispersion of 
specialized skills that are needed 
for different products and stages of 
development [24]. 
Part of the reason for Dendre-
on’s failure with Provenge stemmed 
from the company’s determination 
to undertake a centralized strategy 
when it lacked the skills needed 
for the full suite of activities in the 
market. Arguably, Dendreon would 
have had greater chance of success 
had it been willing to take a more 
decentralized approach, partnering 
with production and marketing 
allies around the world. Yet decen-
tralised commercialization is more 
complex and requires substantially 
more coordination [21].
Complicating the split between 
the centralized and decentralized 
paradigms further is the question 
of logistics. The success of cen-
tralised manufacturing is directly 
tied to efficient logistical networks. 
Conversely, the strength of decen-
tralised manufacturing is the ability 
to overcome logistical challenges of 
dispersion [25]. 
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Some recent initiatives are pro-
viding logistical support for decen-
tralized strategies. Figure 2 depicts 
one such set of services, offered as a 
sequence of cold chain activities by 
multiple firms led by ThermoFisher. 
Rather than depending on the in-
ternal skills of a single supplier , the 
coordinated value chain of multi-
ple suppliers means that companies 
can provide specialized services in a 
high-performance sequence [26].
Another recent decentralization 
initiative arises in the form of scal-
able production sites, such as those 
developed at CCRM in Canada in 
partnership with GE Healthcare 
and at Loughborough University 
in the UK [27,28]. These facilities 
offer the promise of achieving lot 
sizes of several hundred billion to 
trillions of cells, needed for clinical 
testing and ultimately for market 
introduction. The facilities enable 
both economies of scale and reliably 
replicable production. Due to the 
wide variation in potential cell and 
gene therapies currently under sci-
entific investigation, the manufac-
turing platforms of the future are 
likely to need to be developed as 
“process modules” that can be con-
figured to suit the individual prod-
uct being manufactured.
In parallel with the decentral-
ized strategies, expansion by estab-
lished pharmaceutical companies 
into regenerative medicine may be 
resulting in the use of more tradi-
tional centralized approaches. With 
the FDA’s approval of Novartis’s 
CAR-T therapy Kymriah and Gil-
ead’s Yescarta (axicabtagene ciloleu-
cel; obtained with Gilead’s acquisi-
tion of Kite Pharma in Los Angeles) 
in 2017, established pharmaceutical 
companies are becoming increasing-
ly involved in the regenerative med-
icine market. As this engagement 
continues through a mix of internal 
 f FIGURE 2
Progressions in the logistics and cold chain of cell and gene therapies.
With the establishing of the Fisher CryoHub centre to aid distribution, the Cryogatt RFID to manage inventory, the TrakCel system to 
track inventory through the network, and the Asymptote thawing unit, a viable framework for supply of Cell and Gene Therapies is 
emerging.
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development, collaborations, and 
acquisitions (e.g., Celgene’s acqui-
sition of Seattle’s Juno Therapeutics 
in 2018), the participation helps 
validate the technologies and pro-
vides a strong base of regulatory 
and marketing skills. Even such cas-
es, though, have strong decentral-
ized aspects, involving partnerships 
across multiple countries to both 
develop and market the products.
DEMAND SIDE 
CHALLENGES: ACTORS 
IN THE MARKET
Regulatory policy
Navigating a product through the 
global regulatory pathway to market 
approval is a challenging task due to 
the diverse nature of requirements 
each state or region dictates. Addi-
tionally, a product will be regulated 
at differing levels that at first may 
not be clear to the researcher in-
tently focussed on the technological 
aspect. Potential areas include prod-
uct development, manufacturing, 
marketing and promotional activ-
ities, product labelling, and moni-
toring the lifecycle of the invention. 
While these regulatory roles are exe-
cuted differently globally, they share 
the common goal of translating in-
ventions and discoveries safely.
Closer global standardisation 
of regulatory policies would aid in 
market penetration of regenera-
tive medicine products. Regulatory 
agencies have led the way in facil-
itating this market access with the 
progressive rollout of adaptive li-
censing schemes. However, this only 
supports product roll-out so far and 
additional integration would fur-
ther simplify the development path 
for emerging therapies. 
The European Union is an exem-
plar of harmonization of regulatory 
requirements, with the European 
Medicines Agency (EMA) acting as 
a decentralized agency for evaluat-
ing new products. Under this gov-
ernance, companies submit an ap-
plication to the EMA, which gives 
them the freedom of market autho-
rization across the European Union 
as well as the additional countries 
that are members of the European 
Economic Area (Iceland, Liechten-
stein and Norway).
Further convergence initiatives 
could be modelled on learnings 
from the Canadian Excellence in 
Clinical Innovation and Technology 
Evaluation (EXCITE) programme. 
This partnership was established in 
2012 between government bodies, 
the health system, regulators, aca-
demia, clinicians, and industry part-
ners with the goal of harmonizing 
the adoption of products, services, 
and technologies. The primary ad-
vantage of this initiative is quicker 
provisioning of emerging therapies 
to patients. In parallel, for regenera-
tive medicine companies, the accel-
erated adoption process also fosters 
commercial growth.
Although more global regulato-
ry convergence has been slow, in 
part due to the risk-averse nature 
of regulators, both firmer and more 
nuanced regulatory positions are 
emerging. Figure 3 depicts major 
milestones in the global regulatory 
road-map for regenerative medi-
cine, including coordination efforts 
involving the FDA in the U.S., the 
European Medicines Agency, and 
Health Canada. Other convergence 
efforts include the Asia-Pacific Eco-
nomic Cooperation Life Scienc-
es Innovation Forum Regulatory 
Harmonization Steering Com-
mittee,  the International Medical 
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Device Regulators Forum, and the 
Pan American Network for Drug 
Regulatory Harmonization.
Reimbursement & health 
technology assessment
Market entry and expansion re-
quires an effective reimbursement 
strategy. However, substantial vari-
ations in health technology assess-
ment (HTA) and public and private 
reimbursement policies between 
countries and regions denies the po-
tential for a global reimbursement 
strategy for an emerging regenera-
tive medicine therapeutic. With re-
jection rates for medical technology 
adoption in the market running at 
50%-95% even after approval, sub-
stantial market uptake is required 
for successful products. Fragmen-
tation in reimbursement policies 
means that products will be intro-
duced only in some markets or, in 
some cases, not introduced at all.
Reimbursement levels will never 
converge fully across countries due 
to multiple factors, including varia-
tion in local health needs and health 
priorities, as well as local politics 
and differences in ability to pay for 
expensive treatments. Nonetheless, 
greater consistency where feasible 
would facilitate successful commer-
cialization of path-breaking clini-
cal services, particularly in markets 
with compatible priorities. Closer 
convergence of bodies such as the 
 f FIGURE 3
Figure 3. Notable changes along the historical regulatory road-map for regenerative medicine.
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U.K.’s National Institute for Health 
and Care Excellence (NICE), the 
Canadian Agency for Drugs and 
Technologies in Health (CADTH), 
Germany’s Institute for Quality and 
Efficiency in Healthcare (IQWiG), 
and the National High Authority 
for Health (HAS) in France, for 
instance, would simplify the com-
mercial landscape. Progress on har-
monisation of reimbursement likely 
presents a relatively greater chal-
lenge given the high level of uncer-
tainty around the long-term efficacy 
of these advanced therapies. As the 
products become increasingly well 
characterised with regards to safety 
and efficacy, the appetite to simplify 
reimbursement may improve.
Multi-dimensional 
stakeholder engagement
The advanced therapeutics field is 
still evolving, and at this early stage 
it is imperative that key stakehold-
ers become engaged. For instance, 
consider interactions among manu-
facturing, health technology assess-
ment, regulation, and reimburse-
ment. Due to the relative infancy of 
the field, often it is challenging to 
identify factors driving the efficacy of 
the product which in turn dramat-
ically increases the challenge in es-
tablishing an optimal manufacturing 
strategy for a therapy, such as decen-
tralised manufacturing of CAR-T 
therapies in a micro-factory in the 
clinic or rapid 3D bio-printing of re-
placement tissues. These unknowns 
further complicate both regulatory 
negotiations and the value propo-
sition for reimbursement by public 
and private payers. These factors are 
strongly interrelated and it is only 
recently with encouraging efficacy 
data, strong clinical demand, and a 
clearer value proposition that early 
CAR-T therapies have indicated that 
real progress is being made [29].
Patient engagement
Along with cross talk between stake-
holders, it is crucial to have patient 
engagement during the healthcare 
policy decision-making process. Pa-
tient engagement includes patients 
themselves, as well as their families 
and health care providers. These 
opinions can significantly improve 
how health policies are defined and 
executed.  An example of such an 
organization is the independent 
not-for-profit Canadian organiza-
tion, Clinical Trials Ontario, which 
has a team responsible for patient 
and public engagement in clinical 
trials. Similarly, the European Pa-
tient’s Academy (EUPATI) is an 
example of patient engagement 
that supports the involvement of 
patients during the R&D life cycle 
in association with regulatory agen-
cies, health technology assessment 
bodies, ethics boards and the phar-
maceutical industry. 
We stress that rather than waiting 
to engage patients after a product is 
released, it is useful and even essen-
tial to have patient input during 
clinical trial design [30]. In the phar-
maceutical industry, for instance, 
many companies have introduced 
roles for patient representatives to 
contribute to clinical trial advisory 
boards. Patient representatives can 
help shape which indications to fo-
cus on in initial trials and provide 
insight about delivery methods and 
other design questions.
Although immersing oneself 
in patient advocacy can offer re-
lief from the burdens of disease as 
well as help champion direction 
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of resources into under-funded ar-
eas [31], it is important that these 
vested interests do not skew strate-
gic choices to the detriment to the 
broader field [32]. During the 2000s, 
there has been increasing pressure 
from patient advocacy groups to al-
low the right to access experimental 
treatments [33], which runs the risk 
of promoting unproven treatments 
that rely on the human emotion of 
hope [34] more than on evidence. 
Clearly, patient advocates are criti-
cally important but, like all contrib-
utors to the field, they face ethical 
obligations to benefit patients in the 
field as a whole [32].
OPPORTUNITIES GOING 
FORWARD
When examining the history of re-
generative medicine, it is easy to be-
come frustrated by the slow progress. 
The first companies in the field have 
struggled and failed. Yet it is telling 
that the core science and clinical 
practices commonly have been ac-
quired following these failures and 
are often still available from another 
company. This suggests that the sci-
entific approaches are fundamentally 
strong but lack viable market strate-
gies to deliver the clinical and eco-
nomic success they merit.
In the current global climate, 
the value proposition of regenera-
tive medicine therapies has real and 
immediate importance to global 
healthcare markets and must be a 
priority consideration in the clini-
cal translation process. A substan-
tial number of clinical trials are 
reaching Phase III. Even with con-
servative estimates on progression 
through this challenging trials and 
regulatory processes, we should wit-
ness multiple regenerative medicine 
clinical products over the next five 
years. Moreover, the regenerative 
medicine trials market has spread 
globally, with increasing numbers 
of trials occurring outside North 
America or Europe [35]. 
A key issue, though, is that these 
successes are largely driven by tech-
nological push as opposed to market 
pull. This has resulted in scientifi-
cally successful products lacking the 
pre-emptive or concurrent appraisal 
of whether the knowledge can be 
translated into a marketable health-
care product [35]. As we move for-
wards, several profound changes 
should catalyse the roll out of these 
novel therapies.
In order to unlock the global 
potential regenerative medicine 
represents, greater emphasis must 
be placed on global coordination 
of both research and commercial-
ization. This “local to global pivot” 
does not simply emphasise collab-
orating between universities across 
borders. Rather, a wide range of 
stakeholders in the regenerative 
medicine sector need to buy into 
enlarging the scope of collaboration.
Several current examples stand 
out. 
 f Tapping regional expertise for 
global research and development: 
consider CCRM in Canada. This 
government–academic–industry 
convergence point, which includes 
partners in Australia, Sweden the 
UK, and several other countries, 
acts much like the Cell Therapy 
Catapult in the UK in an effort 
to catalyse the translation of 
promising science to products to 
commercialisation. CCRM differs 
in its vision from the UK initiative, 
though, through its explicit strategy 
to make development pathways 
transnational.
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 f Regional replicability of global 
infrastructure: Several current 
initiatives are offering cross-
border services for manufacturing 
and other infrastructural services. 
Progenitor Cell Therapies in New 
Jersey is a contract manufacturer 
that offers transnational 
penetration for manufacturing 
regenerative medicine products, 
including a facility in Japan. 
There has been increasing 
recent interest in the concept of 
such interconnected industrial 
environments, with terms such as 
“Smart Factories” (IBM), “Industrial 
Internet” (GE), “The Factory of the 
Future” (Airbus), and “Industrie 
4.0” (German government) [36,37]. 
These concepts have the potential 
to provide next generation 
manufacturing [38], logistics and 
supply chain management [36], 
smart networks, automation [39] 
and big data [40] that represent 
a paradigm shift from traditional 
centralised manufacturing [41]. 
Critically, they facilitate replicable 
manufacturing and confidence 
in quality in manufacturing sites 
regardless of geography. This is a 
revolutionary catalyst for enabling 
the global regenerative medicine 
manufacturing value chain.
 f Point to point global logistics: 
ThermoFisher Scientific’s CryoHub 
global network has the potential 
to relieve the logistical burden of 
cold chain services. The network 
highlights the recognition that 
even at the development/clinical 
trial manufacturing stage, global 
barriers are detrimental to bringing 
products to market. Technology 
and automation again has much 
to offer here, moving beyond the 
polystyrene dry-shipping box to 
smarter, lighter and fully trackable 
technologies has the potential to 
revolutionise the supply chain of 
advanced therapies.
 f International standards: As 
therapies have progressed 
through trials and manufacturing 
scenarios, compliance typically 
has been enforced through local 
quality management systems that 
build on international guidelines. 
Whilst guidelines such as those 
provided by the International 
Society for Stem Cell Research 
(ISSCR) are useful in providing 
a framework to standardise 
innovative concepts, they are open 
to interpretation and are voluntary. 
Aspects of regenerative medicine 
manufacturing are currently 
governed by the International 
Organization for Standardization 
(ISO), but not the process itself. As 
the field has matured, the ability 
to standardise has become ever 
more possible. ISO standardisation 
is currently being agreed 
internationally; within the coming 
years, this will yield objectively 
measurable minimal standards 
defining the manufacturability of 
regenerative medicine products.
Converting the scientific po-
tential of regenerative medicine 
technology into broad-based ther-
apeutic value remains a significant 
medical and commercial challenge. 
The regenerative medicine field is 
still surrounded by a wide variety 
of scientific, technological, legal, 
and ethical issues that have slowed 
the path to commercial scale and 
clinical usage. If regenerative med-
icine science is to realize its full 
commercial potential, stakeholders 
throughout the sector will need to 
adopt novel coordination strategies 
to overcome these challenges.
EXPERT INSIGHT 
  481Cell & Gene Therapy Insights - ISSN: 2059-7800  
WHO WILL COORDINATE?
The need for global coordination 
points raises a key final question: 
Who will be the coordinators? 
As the sector progresses, much of 
the “local to global pivot” is likely 
to be driven by industry, wheth-
er as consortia or a small number 
of lead firms, possibly in partner-
ship with academic and public al-
lies. Commercial players often are 
most likely to have both the skills 
and the incentives to undertake the 
wide-ranging strategies required to 
achieve successful coordination of 
the globally dispersed knowledge 
and activities that mark the regen-
erative medicine field. 
Nonetheless, despite the clear co-
ordination role for commercial ven-
dors, there is still strong potential 
for academic/government (A/G) 
bodies to function as integrators, 
rather than simply exist as isolated 
entities at the periphery of the com-
mercial ecosystem. A/G integrators 
have strong potential roles in shap-
ing standards, building manufactur-
ing skills, and many other aspects of 
physical and intellectual infrastruc-
ture needed to achieve successful 
commercialization and clinical use 
of regenerative medicine science. 
Such A/G integration is most likely 
to occur in partnerships with com-
mercial vendors, typically with the 
A/G partners taking responsibilities 
for sub-systems within the commer-
cial value chain.  
Traditionally, partnerships with 
industry have been viewed with dis-
trust by many academics and public 
actors. Yet, getting past the distrust 
and finding ways to align indus-
try-academic-public incentives is a 
key part of the global commercial-
ization pathway. Such successful 
relationships will both help A/G 
actors capture part of the commer-
cial value of regenerative medicine 
science and, most importantly, 
smooth the pathway to successful 
translation into broad-based clinical 
value around the world.
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